跳至主要内容
临床试验/IRCT201212206975N3
IRCT201212206975N3已完成2 期

A randomized, double-blind, placebo-controlled pilot study of the efficacy of alendronate on the prevention of bone loss in patients with early ankylosing spondylitis

Vice chancellor for research, Tabriz University of Medical Sciences0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
20

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
All

入选标准

  • Schober index=5; Normal hip joint in the pelvic radiography; Absence or rarity of syndesmophyte in the spine radiography (Taylor index=1); Normal bone density or mild osteopenia (T-score=-1.5)
  • Exclusion criteria:
  • Use of drugs which increase bone density like bisphosphonates; Use of steroids and biological agents; Coexistence of other disease which decreases bone density: including hyperparathyroidism, diabetes, hyper and hypothyroidism, osteomalasia, liver failure, renal failure

排除标准

  • 未提供

研究者

发起方
Vice chancellor for research, Tabriz University of Medical Sciences

相似试验